Genmab Yönetim

Yönetim kriter kontrolleri 4/4

Genmab CEO'su Jan G.J. de Winkel, Jun2010 tarihinde atandı, in görev süresi 15.58 yıldır. in toplam yıllık tazminatı $ 7.61M olup, şirket hissesi ve opsiyonları dahil olmak üzere 17.7% maaş ve 82.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.07% ine doğrudan sahiptir ve bu hisseler $ 231.16M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 7 yıl ve 7.8 yıldır.

Anahtar bilgiler

Jan G.J. de Winkel

İcra Kurulu Başkanı

US$7.6m

Toplam tazminat

CEO maaş yüzdesi	17.70%
CEO görev süresi	15.6yrs
CEO sahipliği	1.1%
Yönetim ortalama görev süresi	7yrs
Yönetim Kurulu ortalama görev süresi	7.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Jan G.J. de Winkel'un ücretlendirmesi Genmab'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2025	n/a	n/a	US$2b
Jun 30 2025	n/a	n/a	US$1b
Mar 31 2025	n/a	n/a	US$1b
Dec 31 2024	US$8m	US$1m	US$1b
Sep 30 2024	n/a	n/a	US$702m
Jun 30 2024	n/a	n/a	US$798m
Mar 31 2024	n/a	n/a	US$791m
Dec 31 2023	US$7m	US$1m	US$645m
Sep 30 2023	n/a	n/a	US$590m
Jun 30 2023	n/a	n/a	US$680m
Mar 31 2023	n/a	n/a	US$757m
Dec 31 2022	US$6m	US$1m	US$785m
Sep 30 2022	n/a	n/a	US$745m
Jun 30 2022	n/a	n/a	US$558m
Mar 31 2022	n/a	n/a	US$354m
Dec 31 2021	US$6m	US$1m	US$452m
Sep 30 2021	n/a	n/a	US$448m
Jun 30 2021	n/a	n/a	US$401m
Mar 31 2021	n/a	n/a	US$880m
Dec 31 2020	US$6m	US$1m	US$781m
Sep 30 2020	n/a	n/a	US$889m
Jun 30 2020	n/a	n/a	US$853m
Mar 31 2020	n/a	n/a	US$349m
Dec 31 2019	US$5m	US$1m	US$325m

Tazminat ve Piyasa: Jan G.J. 'nin toplam tazminatı ($USD 7.61M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 13.29M ).

Tazminat ve Kazançlar: Jan G.J. 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Jan G.J. de Winkel (64 yo)

15.6yrs

Görev süresi

US$7,611,989

Tazminat

Dr. Jan G.J. van de Winkel, Ph.D. was Independent Director of HOOKIPA Pharma Inc. from 2023 until August 30, 2024 and served as Chairman of the Board since 2024 August 30, 2024. Dr. Winkel served as a Memb...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jan G.J. de Winkel	Co-Founder	15.6yrs	US$7.61m	1.07% $ 231.2m
Anthony Pagano	Executive VP & CFO	5.8yrs	US$3.33m	0.011% $ 2.5m
Rayne Waller	Executive VP & Chief Technical Operations Officer	1.4yrs	US$816.76k	Veri yok
Christopher Cozic	Executive VP & Chief People Officer	8.2yrs	US$2.31m	Veri yok
Martine van Vugt	Executive VP & Chief Strategy Officer	12yrs	US$1.51m	Veri yok
Martin Schultz	Senior Director	no data	US$194.47k	0.00065% $ 140.5k
Judith Klimovsky	Executive VP & Chief Development Officer	8.9yrs	US$3.88m	0.018% $ 3.8m
Tahamtan Ahmadi	Executive VP	4.8yrs	US$3.58m	0.0079% $ 1.7m
Mijke Zachariasse	VP, Head of Antibody Research Materials & Director	no data	US$222.25k	0.0011% $ 242.0k
Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director	no data	US$194.47k	0.00013% $ 28.1k
Brad Bailey	Executive VP & Chief Commercial Officer	1.4yrs	US$2.30m	Veri yok
Andrew Carlsen	VP & Head of Investor Relations	no data	Veri yok	Veri yok

7.0yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: GMAB 'un yönetim ekibi deneyimli ve deneyimlidir ( 7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Martin Schultz	Senior Director	4yrs	US$194.47k	0.00065% $ 140.5k
Mijke Zachariasse	VP, Head of Antibody Research Materials & Director	6.8yrs	US$222.25k	0.0011% $ 242.0k
Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director	4yrs	US$194.47k	0.00013% $ 28.1k
Michael Kavanagh	Senior Director	1yr	Veri yok	Veri yok
Anders Pedersen	Non-Independent Director	22.2yrs	US$291.70k	0.013% $ 2.7m
Elizabeth O'Farrell	Independent Director	3.8yrs	US$361.15k	0.0031% $ 661.2k
Deirdre Connelly	Independent Chairman of the Board	8.8yrs	US$458.39k	0.011% $ 2.3m
Rolf Hoffmann	Independent Director	8.8yrs	US$277.81k	0.0061% $ 1.3m
Pernille Erenbjerg	Independent Deputy Chairman	11yrs	US$361.15k	0.0089% $ 1.9m
Paolo Paoletti	Independent Director	11yrs	US$263.92k	0.0041% $ 879.5k

7.8yrs

Ortalama Görev Süresi

59.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: GMAB 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.8 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/01/14 18:58
Gün Sonu Hisse Fiyatı	2026/01/14 00:00
Kazançlar	2025/09/30
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Genmab A/S 45 Bu analistlerden 14, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
James Gordon	Barclays
Xue Chen	Barclays
Emily Field	Barclays

Genmab Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Genmab Announces Changes to Its Executive Committee

Genmab A/S, Annual General Meeting, Mar 12, 2025

Genmab A/S Announces Executive Changes

Genmab A/S Announces Executive Changes

Genmab A/S, Annual General Meeting, Mar 13, 2024

Recent updates

Genmab: AI Partnership And Clinical Data Fuel Growth

Genmab A/S to Discontinue Further Clinical Development of Acasunlimab Following A Portfolio Review

Genmab A/S (CPSE:GMAB) completed the acquisition of Merus N.V. (NasdaqGM:MRUS) in a tender offer transaction.

Genmab A/S Announces EPKINLY (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma

Genmab A/S to Report First Half, 2026 Results on Aug 06, 2026

Genmab Provides Earnings Guidance for the Full Year 2025

Genmab A/S Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®?) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

Genmab Reportedly in Advanced Talks to Buy Merus

Genmab A/S Announces Updated Results from Phase 2 Epcore®? Nhl-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (Dlbcl)

Genmab A/S Raises Earnings Guidance for the Year 2025

Genmab Announces Changes to Its Executive Committee

Genmab A/S Announces Investigational Rinatabart Sesutecan (Rina-S) Demonstrates Encouraging Anti-Tumor Activity Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL-01 Trial

Genmab A/S to Present New and Updated Results from Its Robust Epcoritamab (Epkinly®) Development Program At the 2025 European Hematology Association (Eha) Congress

Genmab A/S to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed Refractory Follicular Lymphoma

Genmab's Outlook Beyond Darzalex's Patent Cliff

Genmab A/S Announces Japan Ministry of Health, Labour and Welfare Approves TIVDAK for the Treatment of Advanced or Recurrent Cervical Cancer

Genmab A/S Updates Data from Cohort B1 of the Phase 1/2 RAINFOL-01 Study of Rina-S

Genmab: GEN3014's Demise And Implications For The HexaBody Platform

Genmab A/S, Annual General Meeting, Mar 12, 2025

Genmab A/S Provides Revenue Guidance for 2025

Genmab A/S Announces New Results from the Phase 1b/2 EPCORE NHL-2 Trial

Genmab Is Too Attractive To Ignore

Genmab: Looking To Manage My Position Around Q3 Earnings

Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate

Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Genmab A/S Takes Full Control of Acasunlimab Development Program

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Genmab: A Complicated Tale

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab Acquires A Missing Piece For Its Pipeline

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab: Recent Updates Support The Growth Narrative

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade)

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Genmab: 3 Trends To Track For A Strong 2024 And Beyond

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Revises Earnings Guidance for the Year 2023

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Genmab reports Q3 worldwide sales of $2.05B for Darzalex

Genmab improves FY 2022 guidance

Genmab reports Q2 worldwide net sales of DARZALEX $1.99B

Genmab: A Royalty Powerhouse With A Strong Pipeline

CEO Tazminat Analizi

CEO

Liderlik Ekibi

Yönetim Kurulu Üyeleri

Şirket Analizi ve Finansal Veri Durumu

Veri Kaynakları